![Julie Hambleton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Julie Hambleton
Director/Board Member at
ERASCA, INC.
Net worth: 77 040 $ as of 31/05/2026
Profile
Julie Hambleton is currently an Independent Director at Erasca, Inc. since 2021, Onc.ai, Inc., and Gennao Bio, Inc. since 2021.
Formerly, Dr. Hambleton was President, Chief Executive Officer & Director at Arch Oncology, Inc. from 2020 to 2021; Director at Accent Therapeutics, Inc. from 2020 to 2021; Independent Director at IGM Biosciences, Inc. from 2018 to 2025; Independent Director at Springworks Therapeutics, Inc. from 2020 to 2025; Vice President & Head-US Medical at Bristol Myers Squibb Co. from 2016 to 2017; Chief Medical Officer & Executive Vice President at Five Prime Therapeutics, Inc. from 2015 to 2016; Associate Professor at The University of California, San Francisco from 1993 to 2003; Vice President-Clinical Development at Clovis Oncology, Inc. from 2010 to 2012; Chief Medical Officer, SVP & Head-Development at IDEAYA Biosciences, Inc. from 2018 to 2020; and Medical Director-Global Clinical Development at Genentech, Inc. from 2003 to 2010.
Education includes undergraduate studies at Duke University and a doctorate from Case Western Reserve University School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 26/06/2026 | 6,000 ( 0% ) | 77 040 $ | 31/05/2026 |
Julie Hambleton active positions
| Companies | Position | Start |
|---|---|---|
| ERASCA, INC. | Director/Board Member | 29/03/2021 |
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted nucleic acid therapeutics to cure muscle diseases | Director/Board Member | 13/07/2021 |
Onc.ai, Inc.
 Onc.ai, Inc. Packaged SoftwareTechnology Services Develops precision oncology care management platform that aims to transform clinical decision making | Director/Board Member | - |
Former positions of Julie Hambleton
| Companies | Position | End |
|---|---|---|
| IGM BIOSCIENCES, INC. | Director/Board Member | 14/08/2025 |
| SPRINGWORKS THERAPEUTICS, INC. | Director/Board Member | 01/07/2025 |
Arch Oncology, Inc.
 Arch Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company that develops biologic therapies for treatment of patients with tumors and hematologic malignancies | Chief Executive Officer | 01/04/2021 |
Accent Therapeutics, Inc.
 Accent Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops treatments for cancer patients | Director/Board Member | 01/03/2021 |
| IDEAYA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 30/04/2020 |
Training of Julie Hambleton
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
86
1st degree connections
15
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 15 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops protein therapeutics for cancer and inflammatory diseases | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as an biopharmaceutical company that acquires, develops and commercializes innovative anti cancer agents | Health Technology |
Arch Oncology, Inc.
Arch Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company that develops biologic therapies for treatment of patients with tumors and hematologic malignancies | Health Technology |
Case Western Reserve University School of Medicine
 Case Western Reserve University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IDEAYA Biosciences, Inc.
 IDEAYA Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as oncology-focused precision medicine company which develops and sells cancer therapeutics | Health Technology |
IGM Biosciences, Inc.
 IGM Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops engineered IgM antibodies for the treatment of cancer patients | Health Technology |
Accent Therapeutics, Inc.
Accent Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops treatments for cancer patients | Health Technology |
Erasca, Inc.
 Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Springworks Therapeutics, Inc.
 Springworks Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes medicines for nervous system disorders | Health Technology |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Develops precision oncology care management platform that aims to transform clinical decision making | Technology Services |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted nucleic acid therapeutics to cure muscle diseases | Health Technology |
- Stock Market
- Insiders
- Julie Hambleton
Choose MarketScreener 
